BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 34168050)

  • 1. The Chronic Lymphocytic Leukemia Comorbidity Index (CLL-CI): A Three-Factor Comorbidity Model.
    Gordon MJ; Kaempf A; Sitlinger A; Shouse G; Mei M; Brander DM; Salous T; Hill BT; Alqahtani H; Choi M; Churnetski MC; Cohen JB; Stephens DM; Siddiqi T; Rivera X; Persky D; Wisniewski P; Patel K; Shadman M; Park B; Danilov AV
    Clin Cancer Res; 2021 Sep; 27(17):4814-4824. PubMed ID: 34168050
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comorbidities predict inferior outcomes in chronic lymphocytic leukemia treated with ibrutinib.
    Gordon MJ; Churnetski M; Alqahtani H; Rivera X; Kittai A; Amrock SM; James S; Hoff S; Manda S; Spurgeon SE; Choi M; Cohen JB; Persky D; Danilov AV
    Cancer; 2018 Aug; 124(15):3192-3200. PubMed ID: 29797667
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The CLL comorbidity index in a population-based cohort: a tool for clinical care and research.
    Rotbain EC; Gordon MJ; Vainer N; Frederiksen H; Hjalgrim H; Danilov AV; Niemann CU
    Blood Adv; 2022 Apr; 6(8):2701-2706. PubMed ID: 35008098
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic models for newly-diagnosed chronic lymphocytic leukaemia in adults: a systematic review and meta-analysis.
    Kreuzberger N; Damen JA; Trivella M; Estcourt LJ; Aldin A; Umlauff L; Vazquez-Montes MD; Wolff R; Moons KG; Monsef I; Foroutan F; Kreuzer KA; Skoetz N
    Cochrane Database Syst Rev; 2020 Jul; 7(7):CD012022. PubMed ID: 32735048
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Medical comorbidities in patients with chronic lymphocytic leukaemia treated with idelalisib: analysis of two large randomised clinical trials.
    Gordon MJ; Huang J; Chan RJ; Bhargava P; Danilov AV
    Br J Haematol; 2021 Feb; 192(4):720-728. PubMed ID: 32599655
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data.
    International CLL-IPI working group
    Lancet Oncol; 2016 Jun; 17(6):779-790. PubMed ID: 27185642
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic impact of chronic lymphocytic leukemia comorbidity index in a young population: a real-world evidence study of a national gulf region cohort.
    Alshemmari SH; AlSarraf A; Kaempf A; Danilov AV
    BMC Cancer; 2024 May; 24(1):584. PubMed ID: 38741031
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeted multigene deep sequencing of Bruton tyrosine kinase inhibitor-resistant chronic lymphocytic leukemia with disease progression and Richter transformation.
    Kanagal-Shamanna R; Jain P; Patel KP; Routbort M; Bueso-Ramos C; Alhalouli T; Khoury JD; Luthra R; Ferrajoli A; Keating M; Jain N; Burger J; Estrov Z; Wierda W; Kantarjian HM; Medeiros LJ
    Cancer; 2019 Feb; 125(4):559-574. PubMed ID: 30508305
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic risk score for patients with relapsed or refractory chronic lymphocytic leukaemia treated with targeted therapies or chemoimmunotherapy: a retrospective, pooled cohort study with external validations.
    Soumerai JD; Ni A; Darif M; Londhe A; Xing G; Mun Y; Kay NE; Shanafelt TD; Rabe KG; Byrd JC; Chanan-Khan AA; Furman RR; Hillmen P; Jones J; Seymour JF; Sharman JP; Ferrante L; Mobasher M; Stark T; Reddy V; Dreiling LK; Bhargava P; Howes A; James DF; Zelenetz AD
    Lancet Haematol; 2019 Jul; 6(7):e366-e374. PubMed ID: 31109827
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-World Clinical Outcomes and Adverse Events in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib: A Single-Center Retrospective Study.
    Moldovianu AM; Stoia R; Vasilica M; Ursuleac I; Badelita SN; Tomescu AA; Preda OD; Bardas A; Cirstea M; Coriu D
    Medicina (Kaunas); 2023 Feb; 59(2):. PubMed ID: 36837525
    [No Abstract]   [Full Text] [Related]  

  • 11. Association of advanced leukemic stage and skin cancer tumor stage with poor skin cancer outcomes in patients with chronic lymphocytic leukemia.
    Velez NF; Karia PS; Vartanov AR; Davids MS; Brown JR; Schmults CD
    JAMA Dermatol; 2014 Mar; 150(3):280-7. PubMed ID: 24429548
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcomes of COVID-19 in patients with CLL: a multicenter international experience.
    Mato AR; Roeker LE; Lamanna N; Allan JN; Leslie L; Pagel JM; Patel K; Osterborg A; Wojenski D; Kamdar M; Huntington SF; Davids MS; Brown JR; Antic D; Jacobs R; Ahn IE; Pu J; Isaac KM; Barr PM; Ujjani CS; Geyer MB; Berman E; Zelenetz AD; Malakhov N; Furman RR; Koropsak M; Bailey N; Hanson L; Perini GF; Ma S; Ryan CE; Wiestner A; Portell CA; Shadman M; Chong EA; Brander DM; Sundaram S; Seddon AN; Seymour E; Patel M; Martinez-Calle N; Munir T; Walewska R; Broom A; Walter H; El-Sharkawi D; Parry H; Wilson MR; Patten PEM; Hernández-Rivas JÁ; Miras F; Fernández Escalada N; Ghione P; Nabhan C; Lebowitz S; Bhavsar E; López-Jiménez J; Naya D; Garcia-Marco JA; Skånland SS; Cordoba R; Eyre TA
    Blood; 2020 Sep; 136(10):1134-1143. PubMed ID: 32688395
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comorbidities at Diagnosis, Survival, and Cause of Death in Patients with Chronic Lymphocytic Leukemia: A Population-Based Study.
    Villavicencio A; Solans M; Zacarías-Pons L; Vidal A; Puigdemont M; Roncero JM; Saez M; Marcos-Gragera R
    Int J Environ Res Public Health; 2021 Jan; 18(2):. PubMed ID: 33467494
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Humoral and cellular immune responses to recombinant herpes zoster vaccine in patients with chronic lymphocytic leukemia and monoclonal B cell lymphocytosis.
    Muchtar E; Koehler AB; Johnson MJ; Rabe KG; Ding W; Call TG; Leis JF; Kenderian SS; Hayman SR; Wang Y; Hampel PJ; Holets MA; Darby HC; Slager SL; Kay NE; Miao C; Canniff J; Whitaker JA; Levin MJ; Schmid DS; Kennedy RB; Weinberg A; Parikh SA
    Am J Hematol; 2022 Jan; 97(1):90-98. PubMed ID: 34699616
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of the CLL-IPI and IPS-E Prognostic Indices in a Young Middle Eastern Population with Chronic Lymphocytic Leukemia: A Retrospective Analysis at the Kuwait Cancer Control Center.
    Alshemmari SH; Alsarraf A; Kunhikrishnan A; Pandita R
    Med Princ Pract; 2023; 32(3):192-199. PubMed ID: 37517397
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-world data on efficacy and safety of obinutuzumab plus chlorambucil, rituximab plus chlorambucil, and rituximab plus bendamustine in the frontline treatment of chronic lymphocytic leukemia: The GO-CLLEAR Study by the Czech CLL Study Group.
    Panovská A; Němcová L; Nekvindová L; Špaček M; Šimkovič M; Papajík T; Brejcha M; Lysák D; Zuchnická J; Novák J; Starostka D; Poul H; Vrbacký F; Vodárek P; Urbanová R; Plevová K; Pospíšilová Š; Mašlejová S; Brychtová Y; Koriťáková E; Smolej L; Doubek M
    Hematol Oncol; 2020 Oct; 38(4):509-516. PubMed ID: 32400885
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of age and comorbidities on the efficacy of FC and FCR regimens in chronic lymphocytic leukemia.
    Strugov V; Stadnik E; Virts Y; Andreeva T; Zaritskey A
    Ann Hematol; 2018 Nov; 97(11):2153-2161. PubMed ID: 29946909
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL) treated with ibrutinib: risk prediction, management, and clinical outcomes.
    Archibald WJ; Rabe KG; Kabat BF; Herrmann J; Ding W; Kay NE; Kenderian SS; Muchtar E; Leis JF; Wang Y; Chanan-Khan AA; Schwager SM; Koehler AB; Fonder AL; Slager SL; Shanafelt TD; Call TG; Parikh SA
    Ann Hematol; 2021 Jan; 100(1):143-155. PubMed ID: 32488603
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of Bruton's kinase inhibitors (BTKi) in accelerated Chronic Lymphocytic Leukemia (a-CLL): a case of successful response to acalabrutinib.
    Catania G; Tavarozzi R; Pini GM; Borra T; Gandolfo C; Zacchi G; Pietrasanta D; Monaco F; Zanni M; Lettieri M; Rivela P; Zallio F; Ladetto M
    J Basic Clin Physiol Pharmacol; 2023 May; 34(3):401-404. PubMed ID: 37040263
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Coexisting conditions and concomitant medications do not affect venetoclax management and survival in chronic lymphocytic leukemia.
    Frustaci AM; Del Poeta G; Visentin A; Sportoletti P; Fresa A; Vitale C; Murru R; Chiarenza A; Sanna A; Mauro FR; Reda G; Gentile M; Varettoni M; Baratè C; Borella C; Greco A; Deodato M; Zamprogna G; Laureana R; Cipiciani A; Galitzia A; Curto Pelle A; Morelli F; Malvisi L; Coscia M; Laurenti L; Trentin L; Montillo M; Cairoli R; Tedeschi A
    Ther Adv Hematol; 2022; 13():20406207221127550. PubMed ID: 36246422
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.